Beam Therapeutics Raises Price Target to $26 and Eyes BLA Submission
RBC Capital lifted Beam Therapeutics’ price target to $26 from $22 and maintained a Sector Perform rating following its fiscal Q4. The company reported $1.25 billion in cash by year-end, secured non-dilutive financing with Sixth Street, and targets a BLA sickle cell submission this year.
1. Rating and Price Target
On February 25, RBC Capital maintained its Sector Perform rating on Beam Therapeutics and increased the price target to $26 from $22 following the release of the company's fiscal Q4 results.
2. Pipeline and Regulatory Plans
Beam is advancing its sickle cell program, risto-cel, with a potential BLA submission slated for later this year and expanding its genetic disease franchise through the BEAM-304 program targeting phenylketonuria, which affects around 20,000 individuals in the U.S.
3. Financing and Cash Position
The company reported cash, cash equivalents, and marketable securities of $1.25 billion as of December 31, 2025, and secured a long-term, non-dilutive financing agreement with Sixth Street to fund potential commercialization without additional equity issuance.
4. Execution Priorities for 2026
Beam’s 2026 strategy focuses on reporting updated Phase 1/2 data, defining the pivotal path for BEAM-302, and preparing for a potential BLA submission for risto-cel by year-end as it advances its lead programs.